Yuyu Pharma Inc
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc.… Read more
Yuyu Pharma Inc (000225) - Total Liabilities
Latest total liabilities as of September 2025: ₩63.32 Billion KRW
Based on the latest financial reports, Yuyu Pharma Inc (000225) has total liabilities worth ₩63.32 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Yuyu Pharma Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Yuyu Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Yuyu Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Yuyu Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Casas Bahia S.A.
SA:BHIA3
|
Brazil | R$31.70 Billion |
|
West Point Gold Corp.
OTCQB:WPGCF
|
USA | $377.98K |
|
RAC Electric Vehicles Inc.
TWO:2237
|
Taiwan | NT$1.72 Billion |
|
Development Advance Solution Co Ltd
KO:058730
|
Korea | ₩177.72 Billion |
|
Pacific West Bancorp
PINK:PWBK
|
USA | $350.38 Million |
|
It's Skin Co Ltd
KO:226320
|
Korea | ₩26.22 Billion |
|
Starbreeze AB (publ)
PINK:STBEF
|
USA | $120.21 Million |
|
Fuel Tech Inc
NASDAQ:FTEK
|
USA | $7.25 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Yuyu Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yuyu Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yuyu Pharma Inc (2014–2024)
The table below shows the annual total liabilities of Yuyu Pharma Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩72.62 Billion | -6.72% |
| 2023-12-31 | ₩77.86 Billion | +8.39% |
| 2022-12-31 | ₩71.83 Billion | +11.71% |
| 2021-12-31 | ₩64.30 Billion | +69.82% |
| 2020-12-31 | ₩37.86 Billion | -19.73% |
| 2019-12-31 | ₩47.17 Billion | -2.44% |
| 2018-12-31 | ₩48.35 Billion | +25.08% |
| 2017-12-31 | ₩38.66 Billion | +17.11% |
| 2016-12-31 | ₩33.01 Billion | +7.88% |
| 2015-12-31 | ₩30.60 Billion | +2.29% |
| 2014-12-31 | ₩29.91 Billion | -- |